Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition
Identifieur interne : 001436 ( Main/Exploration ); précédent : 001435; suivant : 001437Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition
Auteurs : Moussa B. H. Youdim [Israël] ; Orit Bar Am [Israël] ; Merav Yogev-Falach [Israël] ; Orly Weinreb [Israël] ; Wakako Maruyama [Japon] ; Makato Naoi [Japon] ; Tamar Amit [Israël]Source :
- Journal of Neuroscience Research [ 0360-4012 ] ; 2005-01-01.
English descriptors
- KwdEn :
Abstract
Mitochondria are involved directly in cell survival and death. The assumption has been made that drugs that protect mitochondrial viability and prevent apoptotic cascade‐induced mitochondrial permeability transition pore (MPTp) opening will be cytoprotective. Rasagiline (N‐propargyl‐1R‐aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO) B inhibitor anti‐Parkinson drug. Unlike selegiline, it is not derived from amphetamine, and is not metabolized to neurotoxic L‐methamphetamine derivative. In addition, it does not have sympathomimetic activity. Rasagiline is effective as monotherapy or adjunct to levodopa for patients with early and late Parkinson's disease (PD) and adverse events do not occur with greater frequency in subjects receiving rasagiline than in those on placebo. Phase III controlled studies indicate that it might have a disease‐modifying effect in PD that may be related to its neuroprotective activity. Its S isomer, TVP1022, is more than 1,000 times less potent as an MAO inhibitor. Both drugs, however, have neuroprotective activity in neuronal cell cultures in response to various neurotoxins, and in vivo in response to global ischemia, neurotrauma, head injury, anoxia, etc., indicating that MAO inhibition is not a prerequisite for neuroprotection. Their neuroprotective effect has been demonstrated to be associated directly with the propargylamine moiety, which protects mitochondrial viability and MTPp by activating Bcl‐2 and protein kinase C (PKC) and by downregulating the proapoptotic FAS and Bax protein families. Rasagiline and its derivatives also process amyloid precursor protein (APP) to the neuroprotective, neurotrophic, soluble APP α (sAPPα) by PKC‐ and MAP kinase‐dependent activation of α‐secretase. The identification of the propargylamine moiety as the neuroprotective component of rasagiline has led us to development of novel bifunctional anti‐Alzheimer drugs (ladostigil) possessing cholinesterase and brain‐selective MAO inhibitory activity and a similar neuroprotective mechanism of action. © 2004 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/jnr.20350
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition</title><author><name sortKey="Youdim, Moussa B H" sort="Youdim, Moussa B H" uniqKey="Youdim M" first="Moussa B. H." last="Youdim">Moussa B. H. Youdim</name></author><author><name sortKey="Bar Am, Orit" sort="Bar Am, Orit" uniqKey="Bar Am O" first="Orit" last="Bar Am">Orit Bar Am</name></author><author><name sortKey="Yogev Alach, Merav" sort="Yogev Alach, Merav" uniqKey="Yogev Alach M" first="Merav" last="Yogev-Falach">Merav Yogev-Falach</name></author><author><name sortKey="Weinreb, Orly" sort="Weinreb, Orly" uniqKey="Weinreb O" first="Orly" last="Weinreb">Orly Weinreb</name></author><author><name sortKey="Maruyama, Wakako" sort="Maruyama, Wakako" uniqKey="Maruyama W" first="Wakako" last="Maruyama">Wakako Maruyama</name></author><author><name sortKey="Naoi, Makato" sort="Naoi, Makato" uniqKey="Naoi M" first="Makato" last="Naoi">Makato Naoi</name></author><author><name sortKey="Amit, Tamar" sort="Amit, Tamar" uniqKey="Amit T" first="Tamar" last="Amit">Tamar Amit</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E450E10D283690CB4132D34F920FCA3751A0939B</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/jnr.20350</idno><idno type="url">https://api.istex.fr/document/E450E10D283690CB4132D34F920FCA3751A0939B/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000144</idno><idno type="wicri:Area/Main/Curation">000120</idno><idno type="wicri:Area/Main/Exploration">001436</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition</title><author><name sortKey="Youdim, Moussa B H" sort="Youdim, Moussa B H" uniqKey="Youdim M" first="Moussa B. H." last="Youdim">Moussa B. H. Youdim</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, and Rappaport Family Research Institute, Technion‐Faculty of Medicine, Haifa</wicri:regionArea><wicri:noRegion>Haifa</wicri:noRegion></affiliation></author><author><name sortKey="Bar Am, Orit" sort="Bar Am, Orit" uniqKey="Bar Am O" first="Orit" last="Bar Am">Orit Bar Am</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, and Rappaport Family Research Institute, Technion‐Faculty of Medicine, Haifa</wicri:regionArea><wicri:noRegion>Haifa</wicri:noRegion></affiliation></author><author><name sortKey="Yogev Alach, Merav" sort="Yogev Alach, Merav" uniqKey="Yogev Alach M" first="Merav" last="Yogev-Falach">Merav Yogev-Falach</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, and Rappaport Family Research Institute, Technion‐Faculty of Medicine, Haifa</wicri:regionArea><wicri:noRegion>Haifa</wicri:noRegion></affiliation></author><author><name sortKey="Weinreb, Orly" sort="Weinreb, Orly" uniqKey="Weinreb O" first="Orly" last="Weinreb">Orly Weinreb</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, and Rappaport Family Research Institute, Technion‐Faculty of Medicine, Haifa</wicri:regionArea><wicri:noRegion>Haifa</wicri:noRegion></affiliation></author><author><name sortKey="Maruyama, Wakako" sort="Maruyama, Wakako" uniqKey="Maruyama W" first="Wakako" last="Maruyama">Wakako Maruyama</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurosciences, Gifu International Institute of Biotechnology, Kakamigahara Gifu</wicri:regionArea><wicri:noRegion>Kakamigahara Gifu</wicri:noRegion></affiliation></author><author><name sortKey="Naoi, Makato" sort="Naoi, Makato" uniqKey="Naoi M" first="Makato" last="Naoi">Makato Naoi</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Neurosciences, Gifu International Institute of Biotechnology, Kakamigahara Gifu</wicri:regionArea><wicri:noRegion>Kakamigahara Gifu</wicri:noRegion></affiliation></author><author><name sortKey="Amit, Tamar" sort="Amit, Tamar" uniqKey="Amit T" first="Tamar" last="Amit">Tamar Amit</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, and Rappaport Family Research Institute, Technion‐Faculty of Medicine, Haifa</wicri:regionArea><wicri:noRegion>Haifa</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neuroscience Research</title><title level="j" type="abbrev">J. Neurosci. Res.</title><idno type="ISSN">0360-4012</idno><idno type="eISSN">1097-4547</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-01-01">2005-01-01</date><biblScope unit="volume">79</biblScope><biblScope unit="issue">1‐2</biblScope><biblScope unit="page" from="172">172</biblScope><biblScope unit="page" to="179">179</biblScope></imprint><idno type="ISSN">0360-4012</idno></series><idno type="istex">E450E10D283690CB4132D34F920FCA3751A0939B</idno><idno type="DOI">10.1002/jnr.20350</idno><idno type="ArticleID">JNR20350</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0360-4012</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bcl‐2 family members</term><term>SHSY5Y neuroblastoma cells</term><term>caspase‐3</term><term>propargyl moiety</term><term>protein kinase C</term><term>rasagiline</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Mitochondria are involved directly in cell survival and death. The assumption has been made that drugs that protect mitochondrial viability and prevent apoptotic cascade‐induced mitochondrial permeability transition pore (MPTp) opening will be cytoprotective. Rasagiline (N‐propargyl‐1R‐aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO) B inhibitor anti‐Parkinson drug. Unlike selegiline, it is not derived from amphetamine, and is not metabolized to neurotoxic L‐methamphetamine derivative. In addition, it does not have sympathomimetic activity. Rasagiline is effective as monotherapy or adjunct to levodopa for patients with early and late Parkinson's disease (PD) and adverse events do not occur with greater frequency in subjects receiving rasagiline than in those on placebo. Phase III controlled studies indicate that it might have a disease‐modifying effect in PD that may be related to its neuroprotective activity. Its S isomer, TVP1022, is more than 1,000 times less potent as an MAO inhibitor. Both drugs, however, have neuroprotective activity in neuronal cell cultures in response to various neurotoxins, and in vivo in response to global ischemia, neurotrauma, head injury, anoxia, etc., indicating that MAO inhibition is not a prerequisite for neuroprotection. Their neuroprotective effect has been demonstrated to be associated directly with the propargylamine moiety, which protects mitochondrial viability and MTPp by activating Bcl‐2 and protein kinase C (PKC) and by downregulating the proapoptotic FAS and Bax protein families. Rasagiline and its derivatives also process amyloid precursor protein (APP) to the neuroprotective, neurotrophic, soluble APP α (sAPPα) by PKC‐ and MAP kinase‐dependent activation of α‐secretase. The identification of the propargylamine moiety as the neuroprotective component of rasagiline has led us to development of novel bifunctional anti‐Alzheimer drugs (ladostigil) possessing cholinesterase and brain‐selective MAO inhibitory activity and a similar neuroprotective mechanism of action. © 2004 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>Israël</li><li>Japon</li></country></list><tree><country name="Israël"><noRegion><name sortKey="Youdim, Moussa B H" sort="Youdim, Moussa B H" uniqKey="Youdim M" first="Moussa B. H." last="Youdim">Moussa B. H. Youdim</name></noRegion><name sortKey="Amit, Tamar" sort="Amit, Tamar" uniqKey="Amit T" first="Tamar" last="Amit">Tamar Amit</name><name sortKey="Bar Am, Orit" sort="Bar Am, Orit" uniqKey="Bar Am O" first="Orit" last="Bar Am">Orit Bar Am</name><name sortKey="Weinreb, Orly" sort="Weinreb, Orly" uniqKey="Weinreb O" first="Orly" last="Weinreb">Orly Weinreb</name><name sortKey="Yogev Alach, Merav" sort="Yogev Alach, Merav" uniqKey="Yogev Alach M" first="Merav" last="Yogev-Falach">Merav Yogev-Falach</name></country><country name="Japon"><noRegion><name sortKey="Maruyama, Wakako" sort="Maruyama, Wakako" uniqKey="Maruyama W" first="Wakako" last="Maruyama">Wakako Maruyama</name></noRegion><name sortKey="Naoi, Makato" sort="Naoi, Makato" uniqKey="Naoi M" first="Makato" last="Naoi">Makato Naoi</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001436 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001436 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E450E10D283690CB4132D34F920FCA3751A0939B
|texte= Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition
}}
| This area was generated with Dilib version V0.6.23. |  |